<DOC>
	<DOCNO>NCT00031915</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes necessary cancer cell growth . PURPOSE : Phase II trial study effectiveness imatinib mesylate treat patient metastatic unresectable locally advanced soft tissue sarcoma bone sarcoma .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Advanced Soft Tissue Sarcoma Bone Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy imatinib mesylate , measure response rate , patient metastatic unresectable locally advanced soft tissue bone sarcoma fail one prior treatment regimen . - Determine clinical laboratory toxic effect drug patient . OUTLINE : This multicenter study . Patients stratify accord disease subtype . Patients receive oral imatinib mesylate twice daily . Treatment continue 1 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 60-120 patient ( 6-12 per stratum ) accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic unresectable locally advanced ( stage IV recurrent ) soft tissue bone sarcoma Eligible subtypes : Ewing 's family ( e.g. , primitive neuroectodermal tumor ) Osteosarcoma Synovial sarcoma Rhabdomyosarcoma ( e.g. , alveolar , embryonal , pleomorphic ) Liposarcoma ( variant ) Malignant fibrous histiocytoma Peripheral nerve sheath ( e.g. , malignant peripheral nerve sheath tumor , neurofibrosarcoma , schwannoma ) Fibrosarcoma Angiosarcoma ( variant ) Failed standard therapy available salvage regimen Unidimensionally measurable target lesion xray , CT scan , MRI , PET , physical examination Must outside prior irradiation field document disease progression least 6 week completion prior radiotherapy PATIENT CHARACTERISTICS : Age : 10 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) ALT AST less 2.5 time ULN Renal : Creatinine le 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 1 week study participation female patient least 3 month study participation male patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No hormonal birth control Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery : Not specify Other : At least 28 day since prior systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>childhood synovial sarcoma</keyword>
	<keyword>childhood liposarcoma</keyword>
	<keyword>childhood alveolar soft-part sarcoma</keyword>
	<keyword>childhood neurofibrosarcoma</keyword>
	<keyword>childhood angiosarcoma</keyword>
	<keyword>childhood malignant fibrous histiocytoma bone</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>fibrosarcomatous osteosarcoma</keyword>
</DOC>